Skip to main content

Beckman Coulter Reports Surge in Net Income; Revenue, R&D Grows

NEW YORK, July 26 - Beckman Coulter today reported a 4-percent increase in second-quarter revenue, a nudge up in R&D spending, and a strong jump in net income.


For the period ended June 30, the life-sciences tool giant posted an increase in total revenues to just over $516 million from $496 million one year ago. Sales of its clinical diagnostic products inched up 6 percent year over year to $356 million, and sales of its automated genetic-analysis tools jumped 15 percent from the second quarter last year to $43.7 million, the company said.


R&D spending saw a slight increase, to $47.8 million from $47.3 million in the same period one year ago. Second quarter net income, meantime, grew 14 percent to $41.9 million, or $.64 per share, from $36.8 million, or $.58 per share, year over year, the company said.


Beckman Coulter said it had roughly $42.5 million in cash and equivalents as of June 30, 2002, compared with $36 million in the same period one year ago.


Click here for more information.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.